Print This Page
Email to a Friend
 
Perception vs Reality

Incidence of CINV Following MEC Underestimated1

  • Practitioner perception of CINV was less than actually experienced by patients.
  • Despite standard antiemetic treatment (5-HT3 plus corticosteroid; not including ALOXI®), CINV was shown to still be a significant clinical problem.

Patient CINV experience

All patients received a 5-HT3 antagonist (not including Aloxi); 84% received a corticosteroid.

References
  1. Grunberg S., et al. Incidence of Chemotherapy-Induced Nausea and Emesis after Modern Antiemetics: Perception versus Reality, Cancer. 2004;100(number 10):2261-2268.

During initial and repeat courses of chemotherapy, ALOXI helps prevent and control nausea and vomiting the day following chemotherapy that is highly likely to cause nausea and vomiting, and for up to 5 days following chemotherapy that is likely to cause nausea and vomiting. The most frequent side effects of ALOXI include headache and constipation. If you have or may develop significant heart rhythm changes, talk with your healthcare professional before receiving ALOXI.

ALOXI is available by prescription only. Please see the important product information for ALOXI for more information.

This site does not contain everything that is known about ALOXI. If you would like to know more, talk to your healthcare professional.

Prescribing Information | Sitemap | Glossary | Legal Notice | Privacy | Contact Us

This Web site is intended for U.S. residents only.

Distributed and marketed by MGI PHARMA, INC., Bloomington MN 55437
under license of Helsinn Healthcare SA, Switzerland.
© 2007 MGI PHARMA, INC., Bloomington, MN 55437 U.S.A. AL277 9/07

Please see Important Product Information.